Takeda, Zinfandel's AD test fails to deliver
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and partner Zinfandel Pharmaceuticals Inc. (Durham, N.C.) discontinued the Phase III TOMMORROW trial of 0.8 mg pioglitazone (AD-4833) after a planned interim futility analysis showed that the compound was inadequate on the primary endpoint of delaying the onset of mild cognitive impairment (MCI) due to Alzheimer’s disease in high-risk patients. The partners said the decision was not related to safety.
The five-year, double-blind, international trial enrolled over 3,500 cognitively normal individuals and used a genetic-based biomarker risk assignment algorithm to determine the risk of developing MCI due to AD within five years. The algorithm has three components: apolipoprotein E (APOE) genotype, translocase of outer mitochondrial membrane 40 homolog (TOMM40; TOM40) genotype and age. Takeda has exclusive, worldwide rights to develop and commercialize Zinfandel’s TOMM40 assay, including in combination with pioglitazone, to determine risk of AD (see BioCentury, Jan. 17, 2011)...
BCIQ Target Profiles